BAX vs SOLV vs RGEN
161 measures in 16 categories, one definition each, computed from filings and market data.
BAX31.8
Baxter International Inc.
Healthcare · Medical - Instruments & Supplies
$25.28 −1.86%$13.1B mkt cap
Score DNA
SOLV37.3
Solventum Corporation
Healthcare · Medical - Instruments & Supplies
$85.81 −2.34%$14.6B mkt cap
Score DNA
RGEN64.3
Repligen Corporation
Healthcare · Medical - Instruments & Supplies
$175.42 −4.75%$11.1B mkt cap
Score DNA
Price, rebased to 100 three years ago
BAX SOLV RGEN · weekly adjusted closesSmart money 8Valuation 16Profitability (TTM) 12Returns on capital 11Growth 17Margin history & stability 7Liquidity (latest quarter) 7Leverage & solvency (latest quarter) 13Efficiency 11Cash flow & earnings quality 7Dividends & buybacks 9Scores & forensic checks 15Per share 7Size (TTM) 8Price performance 9Technicals 4
● marks the highest or lowest value where that direction is plainly stronger (margins, returns, coverage, leverage); multiples and yields are left unmarked. Bars show each stock's percentile within its own industry. n/a: the measure does not apply to lenders and insurers.
Smart money
8 measures| Measure | BAX | SOLV | RGEN |
|---|---|---|---|
| Insider open-market buys, 180d | 0 | 0 | 0 |
| Insider $ bought, 180d | — | — | — |
| Congress purchases, 180d | 1 | 2 | 0 |
| Last Congress purchase | 2026-05-01 | 2026-05-01 | — |
| 13F net change in holders | +29 | +4 | +38 |
| ETFs adding shares, 30d | 536 | 462 | 378 |
| ETFs trimming, 30d | 397 | 470 | 257 |
| Net ETF funds, 30d | +139 | −8 | +121 |
Valuation
16 measures| Measure | BAX | SOLV | RGEN |
|---|---|---|---|
| P/E (TTM) | — | 10.2x
7th
|
268.1x
87th
|
| PEG (P/E ÷ 3-yr EPS CAGR) | — | — | — |
| Price / sales | 1.1x
12th
|
1.8x
33rd
|
14.2x
96th
|
| Price / book | 2.1x
33rd
|
3.0x
58th
|
5.3x
75th
|
| Price / tangible book | — | — | 11.9x
80th
|
| Price / free cash flow | 19.3x
29th
|
— | 100.5x
90th
|
| Price / operating cash flow | 9.9x
9th
|
69.9x
91st
|
82.6x
95th
|
| Enterprise value | $20.6B
80th
|
$19.5B
76th
|
$11.0B
64th
|
| EV / sales | 1.8x
17th
|
2.3x
46th
|
14.0x
96th
|
| EV / EBITDA | 27.4x
60th
|
7.1x
5th
|
64.8x
90th
|
| EV / EBIT | — | 9.9x
6th
|
142.2x
94th
|
| EV / free cash flow | 30.4x
52nd
|
— | 99.5x
90th
|
| Earnings yield | -8.1%
20th
|
9.8%
96th
|
0.4%
48th
|
| FCF yield | 5.2%
76th
|
-0.8%
8th
|
1.0%
24th
|
| Operating cash flow yield | 10.1%
92nd
|
1.4%
20th
|
1.2%
16th
|
| Graham number (per share) | — | $71.36
64th
|
$24.80
29th
|
Profitability (TTM)
12 measures| Measure | BAX | SOLV | RGEN |
|---|---|---|---|
| Gross margin | 30.1%
12th
|
54.7%
56th
|
51.1%
44th
|
| EBITDA margin | 6.5%
25th
|
32.9%
88th
|
21.7%
71st
|
| Operating margin | -2.4%
17th
|
25.0%
88th
|
8.3%
42nd
|
| EBIT margin | -1.8%
25th
|
23.6%
88th
|
9.9%
58th
|
| Net margin | -9.3%
25th
|
17.3%
88th
|
5.3%
62nd
|
| NOPAT margin | -1.9%
17th
|
21.1%
88th
|
6.6%
50th
|
| FCF margin | 5.9%
33rd
|
-1.4%
8th
|
14.1%
75th
|
| Operating cash flow margin | 11.5%
54th
|
2.5%
12th
|
17.2%
75th
|
| R&D / revenue | 4.5%
29th
|
8.7%
75th
|
7.0%
62nd
|
| SG&A / revenue | 25.6%
33rd
|
39.6%
58th
|
36.9%
50th
|
| Stock comp / revenue | 1.0%
32nd
|
1.5%
48th
|
3.1%
68th
|
| Effective tax rate | 21.0%
36th
|
15.4%
8th
|
20.3%
24th
|
Returns on capital
11 measures| Measure | BAX | SOLV | RGEN |
|---|---|---|---|
| ROE (on average equity) | -15.7%
25th
|
34.0%
100th
|
2.0%
50th
|
| ROA | -5.2%
28th
|
9.8%
84th
|
1.4%
52nd
|
| ROIC | -1.6%
16th
|
18.1%
76th
|
2.6%
28th
|
| ROCE | -1.3%
28th
|
18.5%
84th
|
2.7%
40th
|
| Return on tangible assets | -1.0%
28th
|
13.4%
80th
|
2.6%
48th
|
| Cash ROIC (OCF / invested capital) | 9.6%
60th
|
2.2%
12th
|
6.8%
36th
|
| Gross profitability (GP / assets) | 17.4%
20th
|
31.9%
68th
|
13.6%
4th
|
| ROIC, 3-yr average | 4.6%
62nd
|
7.3%
76th
|
0.7%
43rd
|
| ROIC, 5-yr average | -0.6%
48th
|
— | 4.5%
71st
|
| ROE, 5-yr average | -5.3%
24th
|
— | 3.3%
57th
|
| Incremental ROIC | 8.0%
33rd
|
-104.5%
12th
|
114.2%
71st
|
Growth
17 measures| Measure | BAX | SOLV | RGEN |
|---|---|---|---|
| Revenue growth (TTM YoY) | 5.4%
39th
|
-0.9%
22nd
|
16.5%
87th
|
| Revenue growth (QoQ) | 9.6%
80th
|
10.1%
88th
|
5.1%
52nd
|
| Revenue CAGR, 3 yr | -8.0%
0th
|
— | 3.3%
43rd
|
| Revenue CAGR, 5 yr | -1.2%
16th
|
— | 9.1%
63rd
|
| Gross profit CAGR, 3 yr | -11.0%
0th
|
— | 2.4%
43rd
|
| Operating income CAGR, 3 yr | — | — | -21.4%
7th
|
| Net income growth (TTM YoY) | — | 277.4%
100th
|
— |
| Net income CAGR, 3 yr | — | — | -30.6%
9th
|
| EPS growth (TTM YoY) | — | 279.1%
100th
|
— |
| EPS CAGR, 3 yr | — | — | -30.5%
9th
|
| EPS CAGR, 5 yr | — | — | -16.1%
36th
|
| FCF growth (TTM YoY) | 103.6%
88th
|
— | 4.6%
47th
|
| FCF CAGR, 3 yr | -7.9%
14th
|
— | 29.4%
57th
|
| Operating cash flow CAGR, 3 yr | -5.4%
6th
|
— | -3.2%
12th
|
| Book value CAGR, 3 yr | 2.9%
62nd
|
— | 2.5%
57th
|
| Dividend CAGR, 3 yr | -26.7%
0th
|
— | — |
| Sustainable growth rate | — | 34.0%
100th
|
2.0%
21st
|
Margin history & stability
7 measures| Measure | BAX | SOLV | RGEN |
|---|---|---|---|
| Gross margin, 3-yr average | 35.1%
9th
|
54.6%
50th
|
45.7%
32nd
|
| Operating margin, 3-yr average | 1.4%
32nd
|
15.3%
73rd
|
2.4%
36th
|
| Net margin, 3-yr average | 3.5%
55th
|
8.7%
68th
|
1.1%
45th
|
| FCF margin, 3-yr average | 4.9%
27th
|
4.9%
23rd
|
16.5%
86th
|
| Revenue stability (0-1) | 0.21
9th
|
0.74
52nd
|
0.68
35th
|
| Earnings stability (0-1) | 0.07
9th
|
0.90
91st
|
0.51
57th
|
| Margin stability (0-1) | 0.89
5th
|
1.00
100th
|
0.87
0th
|
Liquidity (latest quarter)
7 measures| Measure | BAX | SOLV | RGEN |
|---|---|---|---|
| Cash & short-term investments | $2.1B
92nd
|
$403.0M
64th
|
$810.4M
80th
|
| Net cash (− = net debt) | −$7.5B
8th
|
−$4.9B
12th
|
$119.5M
72nd
|
| Working capital | $3.4B
92nd
|
$78.0M
8th
|
$1.1B
68th
|
| Current ratio | 1.95
32nd
|
1.02
4th
|
9.05
92nd
|
| Quick ratio | 1.32
32nd
|
0.74
8th
|
7.64
92nd
|
| Cash ratio (cash + ST investments / current liabilities) | 0.60
44th
|
0.11
8th
|
6.11
92nd
|
| Defensive interval (days) | 393 days
48th
|
271 days
40th
|
1,053 days
96th
|
Leverage & solvency (latest quarter)
13 measures| Measure | BAX | SOLV | RGEN |
|---|---|---|---|
| Total debt | $9.7B
92nd
|
$5.3B
88th
|
$690.9M
40th
|
| Debt / equity | 1.56
92nd
|
1.10
88th
|
0.33
38th
|
| Net debt / equity | 1.21
92nd
|
1.02
88th
|
−0.06
38th
|
| Debt / assets | 48.8%
92nd
|
37.1%
80th
|
23.4%
40th
|
| Debt / capital | 60.9%
92nd
|
52.4%
88th
|
24.7%
38th
|
| Debt / EBITDA | 12.89
90th
|
1.94
30th
|
4.06
60th
|
| Net debt / EBITDA | 10.02
90th
|
1.79
50th
|
−0.70
20th
|
| Interest coverage (EBIT / interest) | −0.7x
24th
|
7.4x
76th
|
3.5x
57th
|
| Cash interest coverage | 4.5x
48th
|
0.8x
5th
|
6.1x
52nd
|
| Debt payback (years of OCF) | 7.3 yrs
77th
|
25.3 yrs
100th
|
5.1 yrs
50th
|
| Liabilities / assets | 68.8%
88th
|
66.3%
84th
|
28.4%
28th
|
| IS credit model rating | B+ | BBB- | A |
| Implied credit spread (bps) | 650
84th
|
350
52nd
|
150
32nd
|
Efficiency
11 measures| Measure | BAX | SOLV | RGEN |
|---|---|---|---|
| Asset turnover | 0.56
52nd
|
0.57
56th
|
0.27
4th
|
| Fixed asset turnover | 3.61
52nd
|
5.31
76th
|
2.77
28th
|
| Inventory turnover | 3.5
60th
|
3.8
68th
|
2.2
28th
|
| Receivables turnover | 6.3
52nd
|
7.0
60th
|
5.0
12th
|
| Days sales outstanding | 58 days
48th
|
52 days
40th
|
73 days
88th
|
| Days inventory outstanding | 106 days
40th
|
97 days
32nd
|
163 days
72nd
|
| Days payables outstanding | 46 days
36th
|
65 days
68th
|
28 days
12th
|
| Cash conversion cycle (days) | 117 days
36th
|
84 days
24th
|
208 days
88th
|
| Capex / revenue | 5.6%
75th
|
3.9%
50th
|
3.1%
33rd
|
| Capex / depreciation | 0.67
71st
|
0.43
42nd
|
0.26
12th
|
| Operating expense ratio | 27.5%
17th
|
50.0%
75th
|
47.2%
62nd
|
Cash flow & earnings quality
7 measures| Measure | BAX | SOLV | RGEN |
|---|---|---|---|
| Operating cash flow / net income | — | 0.15
7th
|
3.25
73rd
|
| FCF / net income | — | −0.08
7th
|
2.67
73rd
|
| FCF / operating cash flow | 51.4%
24th
|
-56.5%
0th
|
82.1%
71st
|
| Capex / operating cash flow | 48.6%
76th
|
156.5%
100th
|
17.9%
29th
|
| Accruals ratio | -11.7%
28th
|
8.4%
100th
|
-3.2%
76th
|
| Sloan accruals ratio | -6.7%
24th
|
-8.7%
12th
|
1.4%
72nd
|
| Earnings quality score (0-1) | — | 0.25
0th
|
1.00
47th
|
Scores & forensic checks
15 measures| Measure | BAX | SOLV | RGEN |
|---|---|---|---|
| IS score | 32
12th
|
37
28th
|
64
72nd
|
| IS profitability | 18
24th
|
55
80th
|
24
40th
|
| IS growth | 37
13th
|
59
52nd
|
68
87th
|
| IS value | 39
20th
|
67
100th
|
41
44th
|
| IS momentum | 38
13th
|
49
26th
|
95
100th
|
| IS risk (safety) | 50
16th
|
50
16th
|
100
72nd
|
| IS quality | 33
8th
|
52
44th
|
73
72nd
|
| IS balance sheet | 34
8th
|
49
44th
|
74
60th
|
| IS earnings quality | 43
36th
|
35
16th
|
74
68th
|
| IS cash flow | 45
36th
|
3
0th
|
61
68th
|
| Piotroski F-score (0-9) | 3
0th
|
7
68th
|
8
84th
|
| Altman Z-score | 2.2
36th
|
2.1
32nd
|
6.5
76th
|
| Beneish M-score | −2.98
30th
|
−2.08
91st
|
−2.66
52nd
|
| Ohlson O-score | −6.41
80th
|
−7.35
64th
|
−9.84
16th
|
| IS credit score | 30
16th
|
51
44th
|
72
68th
|
Size (TTM)
8 measures| Measure | BAX | SOLV | RGEN |
|---|---|---|---|
| Market cap | $13.1B
76th
|
$14.6B
80th
|
$11.1B
72nd
|
| Revenue | $11.5B
92nd
|
$8.3B
84th
|
$785.1M
32nd
|
| EBITDA | $750.0M
68th
|
$2.7B
92nd
|
$170.1M
44th
|
| Net income | −$1.1B
0th
|
$1.4B
92nd
|
$41.5M
52nd
|
| Free cash flow | $678.0M
80th
|
−$118.0M
4th
|
$110.8M
36th
|
| Total assets | $19.8B
88th
|
$14.2B
84th
|
$3.0B
40th
|
| Shareholders' equity | $6.2B
76th
|
$4.8B
68th
|
$2.1B
44th
|
| Employees | 37,500
92nd
|
20,584
88th
|
2,000
32nd
|
Price performance
9 measures| Measure | BAX | SOLV | RGEN |
|---|---|---|---|
| 1 day | −1.9% | −2.3% | −4.8% |
| 1 week | +3.8% | −1.7% | +0.9% |
| 1 month | +9.8% | −2.0% | −1.6% |
| 3 months | +14.6% | +8.3% | +20.6% |
| 6 months | +35.3% | +21.7% | +33.7% |
| Year to date | +29.8% | +8.6% | +6.7% |
| 1 year | +11.4% | +19.9% | +17.3% |
| 3 years, cumulative | −18.4% | — | +12.2% |
| 5 years, cumulative | −65.2% | — | −32.2% |
Technicals
4 measures| Measure | BAX | SOLV | RGEN |
|---|---|---|---|
| RSI 14 | 59.5 | 42.4 | 48.8 |
| From 52-week high | −15.7% | −8.9% | −11.8% |
| From 52-week low | +60.9% | +37.5% | +73.7% |
| Beta | 0.65 | 0.70 | 1.08 |
InsiderStreet reports findings from filings and market data. A comparison is not a recommendation to buy or sell either stock.Every figure is computed in code · data as of 2026-10-17